Phase II Trial of Ra-223 dichloride in combination with Hormonal Therapy and Denosumab in the Treatment of Patients with Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Trial Profile

Phase II Trial of Ra-223 dichloride in combination with Hormonal Therapy and Denosumab in the Treatment of Patients with Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Denosumab (Primary) ; Radium 223 chloride (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 01 Apr 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov.
    • 01 Apr 2016 Protocol amended as dose of Ra-223 dichloride changed from 50 kBq/kg - 55kBq/kg as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top